44 results
Page 2 of 3
8-K
EX-99.1
qpv1sdta8p9
9 Mar 22
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
4:05pm
8-K
EX-99.1
iwlxf37bnf15ws
11 Jan 22
Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones
9:00am
8-K
EX-99.1
oovxuaw
29 Sep 21
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
4:42pm
8-K
EX-99.1
8suenfhtf rf5
20 Aug 21
Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors
12:00am
8-K
EX-99.1
05ivjnivk3
5 Aug 21
Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
4:36pm
8-K
EX-99.1
3q7s2nlp y8uj6bd8tr9
9 Jun 21
Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors
4:17pm
8-K
EX-99.1
km786d84
6 May 21
Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
4:06pm
8-K
EX-99.1
djobva9u
9 Mar 21
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates
4:05pm
8-K
EX-99.1
we5f9cxlitl77p 9g2
12 Jan 21
Mirum Pharmaceuticals Provides Corporate Update
9:10am
8-K
zjcwcd6dxiwn
15 Dec 20
Other Events
5:09pm
424B5
bv9s 9oyl0xv
15 Dec 20
Prospectus supplement for primary offering
4:57pm
424B5
xshpx 91yh9dtv98qb
14 Dec 20
Prospectus supplement for primary offering
7:13am
8-K
EX-99.1
nr3 jq3jfxmhb
12 Nov 20
Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day
6:06am